Carlson curve
The Carlson Curve is a term coined by The Economist[1] to describe the biotechnological equivalent of Moore's law, and is named after author Rob Carlson.[2] Carlson predicted that the doubling time of DNA sequencing technologies (measured by cost and performance) would be at least as fast as Moore's law.[3] Carlson Curves illustrate the rapid (in some cases above exponential growth) decreases in cost, and increases in performance, of a variety of technologies, including DNA sequencing, DNA synthesis and a range of physical and computational tools used in protein production and in determining protein structures.
Moore's Law started being profoundly out-paced in January 2008 when the centers transitioned from Sanger sequencing to newer DNA sequencing technologies :[4]
- 454 sequencing (average read length=300-400 bases): 10-fold
- Illumina and SOLiD sequencing (average read length=50-100 bases): 30-fold.
References
- ^ "Life 2.0". The Economist. August 31, 2006.
- ^ Robert H. Carlson (April 2011). Biology Is Technology : The Promise, Peril, and New Business of Engineering Life. Cambridge, MA: Harvard University Press.
- ^ Robert Carlson (September 2003). "The Pace and Proliferation of Biological Technologies". Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. 1 (3: 203-214). Mary Ann Liebert, Inc. doi:10.1089/153871303769201851.
- ^ "DNA Sequencing Costs". National Human Genome Research Institute.
 | This genetics article is a stub. You can help Wikipedia by expanding it. |